Orgenesis Inc.
ORGS · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.33 | 0.34 | 0.06 | 0.00 |
| FCF Yield | -2.23% | -2.34% | -2.41% | -3.52% |
| EV / EBITDA | -29.67 | -33.13 | -24.95 | -0.86 |
| Quality | ||||
| ROIC | -996.44% | -161.45% | -164.71% | -4,219.78% |
| Gross Margin | -68.59% | -304.47% | -437.59% | 123.30% |
| Cash Conversion Ratio | 0.46 | 0.66 | 0.45 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 20.65% | -27.19% | -733.93% | 62.39% |
| Safety | ||||
| Net Debt / EBITDA | -2.23 | -1.61 | -3.10 | -0.50 |
| Interest Coverage | -8.13 | -6.37 | -11.07 | -133.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 22.29 | 93.21 |
| Cash Conversion Cycle | -1,381.97 | -1,125.43 | -1,787.28 | -202.98 |